<DOC>
	<DOCNO>NCT00203476</DOCNO>
	<brief_summary>To compare LDL reduction compare baseline patient use maximum tolerated HMG CoA Reductase inhibitor ( statin ) therapy adjunctive therapy ezetimibe , colestipol , niacin . The patient 's cardiovascular risk assess determine National Cholesterol Education Program 's Adult Treatment Panel III ( NCEP ATP III ) guideline low density lipoprotein ( LDL ) reduction achieve three group . Secondary measure examine safety issue liver function test ( LFT ) monitoring rhabdomyolysis . High-density lipoprotein ( HDL ) elevation monitor three group determine efficacy secondary outcome .</brief_summary>
	<brief_title>A Prospective , Open Label Comparison Ezetimibe , Niacin , Colestipol Adjunct Therapy Lipid Reduction</brief_title>
	<detailed_description>: Patients hyperlipidemia sign consent currently maximum tolerate dose statin meeting NCEP ATPIII treatment goal LDL cholesterol enrol 12-week open label , prospective trial . Patients randomize one three group receive ezetimibe , niacin , colestipol addition current statin therapy . Patients titrate tolerated therapeutic dos study medication ( ezetimibe 10mg/day , niacin 1500mg/day , colestipol 20gm/day ) . At baseline , informed consent ; laboratory admission profile ( Chem20 ) ; weight ; height ; blood pressure ; concomitant medication ; cholesterol medication history ; grapefruit juice consumption data gather . At week 6 12 , patient cholesterol panel liver function test assess . Patients also interview regard side effect ( include rhabdomyolysis ) , tolerance , change concomitant medication , grapefruit juice consumption , along weight blood pressure measurement .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Colestipol</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Veterans eligible treatment Tuscaloosa VA Medical Center 50 year age Male female Any race ethnic group Signed inform consent Hyperlipidemia despite current maximum tolerate dose HMG CoA Reductase inhibitor ( statin ) &gt; 6 week Currently meet NCEP ATPIII treatment goal LDL cholesterol Known hypersensitivity intolerance ezetimibe , niacin , colestipol Previous fail adequate trial adjunctive ezetimibe , niacin , colestipol Consumes 8oz . grapefruit juice daily Significant medical condition would impact safety evaluation ( i.e . significantly elevate LFT , hepatitis , severe dermatitis , uncontrolled diabetes , severe GI disease , fibromyalgia , renal failure , recent CVA MI , pancreatitis , etc . ) Receiving medication would contraindicate use combination ezetimibe , niacin , colestipol</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>ezetimibe</keyword>
	<keyword>niacin</keyword>
	<keyword>colestipol</keyword>
	<keyword>hyperlipidemia</keyword>
	<keyword>adjunct therapy</keyword>
	<keyword>zetia</keyword>
</DOC>